Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019 Year: 2019
How frequent is bronchodilator reversibility in patients with stable asthma bronchiale and chronic obstructive lung disease (COPD) receiving maintenance therapy? Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012
The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Salmeterol/fluticasone therapy improves FEV1 in mild and moderate more than in severe COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004
Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline Source: International Congress 2018 – COPD management Year: 2018
Extrafine triple therapy in patients with asthma and persistent airflow limitation Source: Eur Respir J, 56 (3) 2000476; 10.1183/13993003.00476-2020 Year: 2020
Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Influence of statin therapy on exacerbation frequency in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Effect of roflumilast in patients with severe COPD and a history of hospitalisation Source: Eur Respir J, 50 (1) 1700158; 10.1183/13993003.00158-2017 Year: 2017
Impact of moderate and severe exacerbations in severe COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018
The effects of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients Source: Annual Congress 2006 - COPD therapy Year: 2006
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001
Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007
Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids Source: Annual Congress 2006 - COPD therapy Year: 2006
The safety of sputum induction in patients with exacerbation of severe and very severe COPD (chronic obstructive pulmonary disease) Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008
Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD Source: Annual Congress 2006 - COPD therapy Year: 2006
Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018